# Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock

> **NCT00420030** · PHASE4 · COMPLETED · sponsor: **Charles University, Czech Republic** · enrollment: 80 (estimated)

## Conditions studied

- Shock, Cardiogenic

## Interventions

- **DRUG:** Abciximab

## Key facts

- **NCT ID:** NCT00420030
- **Lead sponsor:** Charles University, Czech Republic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2009-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420030, "Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00420030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*